Quanterix Balances Growth Ambitions with Organic Weakness

Quanterix ((QTRX)) has held its Q1 earnings call. Read on for the main highlights of the call.

Quanterix’s latest earnings call painted a cautiously optimistic picture as management balanced solid reported growth with clear warnings about end‑market weakness. Revenue rose 20% on a reported basis and non‑GAAP gross margins held above 50%, supported by sizable cost synergies and a strong cash position. Yet sharp organic declines in core Simoa and spatial lines, weaker pharma demand and instrumentation softness underscored that the turnaround still depends heavily on execution rather than market recovery.

Total Revenue Growth Masks Organic Weakness

Quanterix reported Q1 2026 revenue of $36.4 million, up 20% year over year, helped by acquisitions and partner revenue. However, management noted that organic revenue fell 21%, highlighting how much of the top‑line progress stems from portfolio additions rather than underlying demand.

Diagnostics Partner Momentum Builds

Revenue from diagnostics partners almost doubled to $2.9 million from $1.6 million a year earlier, reflecting growing volume for single‑biomarker tests from enablement partners. This expansion signals increasing adoption of Quanterix technology in clinical workflows even as broader diagnostics revenue remains modest.

Installed Base Underpins Long-Term Growth Story

The company now counts more than 2,300 instruments in the field and continues to pitch Simoa as a leader in ultrasensitive digital immunoassays and its spatial platform as the highest‑plex proteomic system. Management argued that this installed base and technology positioning give Quanterix leverage to capture incremental consumables and services revenue over time.

Cost Synergies from Akoya Acquisition Realized

Quanterix delivered the $85 million of annualized cost synergies it had committed to from the Akoya acquisition and will stop reporting these figures after this quarter. The company framed this milestone as a key step toward improving profitability, freeing resources to reinvest in growth and commercial capabilities.

Non-GAAP Gross Margins Remain Robust

Non‑GAAP gross profit reached $18.5 million, translating to a non‑GAAP gross margin of 50.9% in Q1. Management reiterated full‑year non‑GAAP gross margin guidance of 49% to 53%, suggesting they see current levels as sustainable despite the ongoing mix shifts and accounting reclassifications.

Adjusted EBITDA and Cash Usage Trending Better

Adjusted EBITDA loss narrowed to $9.8 million, a sequential improvement of $1.5 million as synergy benefits and cost controls flowed through. Adjusted cash usage stood at $14.7 million in the quarter, and the company expects outflows to decline now that certain annual payments are behind it.

Balance Sheet Strength with No Debt

At quarter end, Quanterix held $102.6 million in cash, cash equivalents, marketable securities and restricted cash and carried no debt. Management expects to finish 2026 with roughly $100 million of cash, emphasizing the company’s flexibility to fund investments while working toward cash‑flow breakeven.

Targeted Investments in Commercial and Diagnostics

Management is stepping up commercial investments, including hiring a senior pharma partnerships leader, expanding lead generation efforts, building market development teams and integrating Thermo Fisher as a distributor. On the diagnostics side, Quanterix is upgrading the Simoa HD‑X platform for future regulatory submissions, enhancing lab infrastructure and supporting clinical utility studies to prepare for broader clinical adoption.

Partnerships and Product Roadmap Streamlined

A key highlight was the partnership with Tempus AI to integrate the LucentAD Complete test into select electronic health record systems, which could ease clinician uptake. Internally, Quanterix is streamlining its product roadmap to focus on HD‑X and incorporate lessons from the Simoa ONE early access program, aiming to sharpen R&D priorities and execution.

Organic Revenue Declines Highlight Core Weakness

Despite headline growth, organic revenue dropped 21% year over year, signaling meaningful weakness in the core business. Simoa and spatial revenues both declined organically, falling 21% and 26% respectively, underscoring ongoing pressure in research‑tool spending.

Soft Instrumentation Sales and Deferred Deals

Instrumentation revenue was only $4.0 million, split between $2.3 million for Simoa and $1.7 million for spatial systems, with some deals slipping into Q2. The company placed 16 Simoa and 11 spatial instruments, and management stressed that closing deferred transactions will be important for second‑quarter momentum.

Pharma and Academic Demand Under Pressure

Pharma revenue declined 33% year over year, largely due to fewer large accelerator projects and reduced spatial instrument placements. Pro forma academic revenue slipped about 16%, notable given academia accounts for roughly 65% of the customer mix and remains a key driver of consumables demand.

Heavy One-Time and Acquisition-Related Charges

Operating expenses totaled $56.9 million and included around $22 million of acquisition, integration, restructuring and purchase‑accounting costs. A notable component was a $19 million write‑off of an intangible asset tied to the termination of an Akoya diagnostics development agreement, highlighting the integration’s accounting noise.

Ongoing Adjusted EBITDA Loss and Cash Burn

Even with improvement, adjusted EBITDA remained negative at a $9.8 million loss for the quarter. The company used $19 million of cash overall, or $14.7 million on an adjusted basis, leaving investors focused on the pace of future cash burn as Quanterix invests in growth initiatives.

Diagnostics Revenue Outlook Remains Conservative

Management is taking a cautious stance on near‑term diagnostics contributions, not planning on direct testing revenue in 2026 and expecting partner‑driven diagnostics revenue to stay around 2025 levels of roughly $10 million. This conservative posture implies that meaningful diagnostics upside is more likely a medium‑term story than a near‑term growth engine.

End-Market Headwinds Persist

Executives acknowledged that end markets remain challenging, citing academic funding slowdowns and softer demand early in the year. They cautioned that most growth in the near term is expected to come from internal initiatives rather than a broad rebound in research or pharma spending.

Forward Guidance Balances Ambition and Caution

Quanterix reaffirmed its full‑year 2026 outlook for revenue between $169 million and $174 million, with GAAP gross margins of 41% to 45% and non‑GAAP margins of 49% to 53%. Management expects Q2 revenues to come in roughly in line with or slightly above Q1 and is targeting cash‑flow breakeven in the second half of 2026 while ending the year with about $100 million in cash and no debt.

Quanterix’s earnings call underscored a complex mix of progress and pressure, with reported growth, strong gross margins and delivered synergies set against weak organic trends and cautious demand signals. For investors, the story now hinges on whether commercial initiatives, a growing installed base and diagnostics partnerships can offset persistent end‑market headwinds and move the company toward its 2026 profitability and cash‑flow goals.